We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA, 고위험 NMIBC에 대해 durvalumab과 BCG 병용요법 승인. POTOMAC 데이터: 32% 위험 감소. 효능, 독성, BCG 부족의 영향 분석. 자세히 알아보기.
